An Introduction to Tirzepatide

Overview

Journal Clin Diabetes

Specialty Endocrinology

Date 2022 Aug 19

PMID 35983423

Authors

Taylor Bertsch

Affiliations

Soon will be listed here.

Citing Articles

Multiple nanotechnological approaches using natural compounds for diabetes management.

Stoleru O, Burlec A, Mircea C, Felea M, Macovei I, Hancianu M J Diabetes Metab Disord. 2024; 23(1):267-287.

PMID: 38932892 PMC: 11196251. DOI: 10.1007/s40200-023-01376-1.

Diabetology and Nanotechnology: A Compelling Combination.

Karwasra R, Sharma S, Sharma I, Shahid N, Umar T Recent Pat Nanotechnol. 2023; 19(1):4-16.

PMID: 37937555 DOI: 10.2174/0118722105253055231016155618.

Emerging therapeutic options in the management of diabetes: recent trends, challenges and future directions.

Ansari M, Chauhan W, Shoaib S, Alyahya S, Ali M, Ashraf H Int J Obes (Lond). 2023; 47(12):1179-1199.

PMID: 37696926 DOI: 10.1038/s41366-023-01369-3.

Current Advances in the Management of Diabetes Mellitus.

Aloke C, Egwu C, Aja P, Obasi N, Chukwu J, Akumadu B Biomedicines. 2022; 10(10).

PMID: 36289697 PMC: 9599361. DOI: 10.3390/biomedicines10102436.

References

Frias J, Davies M, Rosenstock J, Perez Manghi F, Lando L, Bergman B . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515. DOI: 10.1056/NEJMoa2107519. View

Coskun T, Sloop K, Loghin C, Alsina-Fernandez J, Urva S, Bokvist K . LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018; 18:3-14. PMC: 6308032. DOI: 10.1016/j.molmet.2018.09.009. View

Holst J, Gasbjerg L, Rosenkilde M . The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology. 2021; 162(7). PMC: 8168943. DOI: 10.1210/endocr/bqab065. View

Tan T, Khoo B . Tirzepatide and the new era of twincretins for diabetes. Lancet. 2021; 398(10295):95-97. DOI: 10.1016/S0140-6736(21)01390-8. View

Rosenstock J, Wysham C, Frias J, Kaneko S, Lee C, Lando L . Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021; 398(10295):143-155. DOI: 10.1016/S0140-6736(21)01324-6. View